Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LBL-024 + bevacizumab
- Development stage
- Unknown
- Lead developer
- LEADS BioLabs
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
LBL-024 + bevacizumab is a combination regimen comprising **LBL-024**, a bispecific monoclonal antibody targeting PD-L1 and 4-1BB, and **bevacizumab**, a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A). LBL-024 blocks immune suppression mediated by PD-1/PD-L1 and conditionally activates 4-1BB-co-stimulatory signaling to potentiate anti-tumor T-cell responses, while bevacizumab inhibits VEGF signaling to block angiogenesis, thereby preventing tumor blood vessel formation and growth. This combination is under investigation in advanced non-small cell lung cancer (NSCLC), aiming to synergistically enhance both **immune activation against tumor cells and suppression of tumor angiogenesis**[1][3][4][7][8][10].
- Brand names
- LBL-024 + bevacizumab
- Other names
- LBL-024 + bevacizumab
02
Targets
TNFRSF9 (CD137 extracellular domain)VEGFA (Vascular endothelial growth factor A)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on LBL-024 + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LBL-024 + bevacizumab.